Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrđan Verstovšek, Alessandra Iurlo, Yeow Tee Goh et al.|The Lancet|2023Cited by 181
Avapritinib versus Placebo in Indolent Systemic MastocytosisJason Gotlib, Robyn M. Scherber, Mariana Castells et al.|NEJM Evidence|2023Cited by 74
Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinibFrancesca Palandri, Andrew Kuykendall, Filippo Branzanti et al.|Cancer|2025Cited by 5
Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK InhibitionNico Gagelmann, Nicolaus Kröger, Bárbara Mora et al.|Blood|2024Cited by 3